Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation.
BMD
DXA
allogeneic HCT
zoledronate
Journal
Blood cell therapy
ISSN: 2432-7026
Titre abrégé: Blood Cell Ther
Pays: Japan
ID NLM: 9918333884906676
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
01
12
2020
accepted:
16
03
2021
entrez:
30
1
2023
pubmed:
25
8
2021
medline:
25
8
2021
Statut:
epublish
Résumé
There is a lack of prospective studies to address the issue of timing of bone mineral density (BMD) measurement and anti-resorptive therapy before and after allogeneic hematopoietic cell transplantation (allo-HCT), specifically in the younger population (age < 40 years). This study evaluated the incidence and risk factors of poor BMD in young Indian patients undergoing allogeneic hematopoietic cell transplant and the effect of anti-resorptive therapy in allogeneic transplant recipients who are at high risk for severe bone loss. This was a single-center, prospective study conducted from 2016 to 2019. All patients aged ≥ 12 years undergoing allo-HCT were included in the study. Data regarding the risk factors for osteoporosis, underlying diagnoses, and HCT characteristics were recorded. BMD was measured by dual-energy X-ray absorptiometry (DXA) (HOLOGIC Discovery A) at the lumbar spine (LS), femoral neck (FN), and total hip (TH) at pre-HCT, day+100, and day+365 post-HCT. Patients with Z-score ≤ -2 at day+100 were given one dose (4 mg) of intravenous zoledronate. Patients with moderate to severe chronic graft-versus-host disease (GVHD) also received a dose of zoledronate if they had not received it earlier. The median age of our cohort was 24 years (IQR 18.5 - 39.5). Day+100 DXA was available for 25 (54.3%) patients, a paired day+100, and day+365 DXA was available for 15 patients. For pre-HCT, a Z-score ≤ -2 was seen in 30% of patients. For day+100 post-HCT, a Z-score ≤ -2 was seen in 44% of patients. Low body mass index was associated with a Z-score ≤ -2 (median 18 vs. 23 kg/m BMD below the expected range for age (Z-score ≤ -2) was present in one-third of young Indian patients undergoing allo-HCT in this single center study. Without intervention, up to half of the patients had a Z-score ≤ -2 at day+100 post-HCT. BMD loss at day+100 persisted at day+365 despite anti-resorptive therapy.
Sections du résumé
Background
UNASSIGNED
There is a lack of prospective studies to address the issue of timing of bone mineral density (BMD) measurement and anti-resorptive therapy before and after allogeneic hematopoietic cell transplantation (allo-HCT), specifically in the younger population (age < 40 years). This study evaluated the incidence and risk factors of poor BMD in young Indian patients undergoing allogeneic hematopoietic cell transplant and the effect of anti-resorptive therapy in allogeneic transplant recipients who are at high risk for severe bone loss.
Methods
UNASSIGNED
This was a single-center, prospective study conducted from 2016 to 2019. All patients aged ≥ 12 years undergoing allo-HCT were included in the study. Data regarding the risk factors for osteoporosis, underlying diagnoses, and HCT characteristics were recorded. BMD was measured by dual-energy X-ray absorptiometry (DXA) (HOLOGIC Discovery A) at the lumbar spine (LS), femoral neck (FN), and total hip (TH) at pre-HCT, day+100, and day+365 post-HCT. Patients with Z-score ≤ -2 at day+100 were given one dose (4 mg) of intravenous zoledronate. Patients with moderate to severe chronic graft-versus-host disease (GVHD) also received a dose of zoledronate if they had not received it earlier.
Results
UNASSIGNED
The median age of our cohort was 24 years (IQR 18.5 - 39.5). Day+100 DXA was available for 25 (54.3%) patients, a paired day+100, and day+365 DXA was available for 15 patients. For pre-HCT, a Z-score ≤ -2 was seen in 30% of patients. For day+100 post-HCT, a Z-score ≤ -2 was seen in 44% of patients. Low body mass index was associated with a Z-score ≤ -2 (median 18 vs. 23 kg/m
Conclusions
UNASSIGNED
BMD below the expected range for age (Z-score ≤ -2) was present in one-third of young Indian patients undergoing allo-HCT in this single center study. Without intervention, up to half of the patients had a Z-score ≤ -2 at day+100 post-HCT. BMD loss at day+100 persisted at day+365 despite anti-resorptive therapy.
Identifiants
pubmed: 36711058
doi: 10.31547/bct-2020-019
pmc: PMC9847263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48-53Informations de copyright
Copyright Ⓒ2021 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website.
Références
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
Indian J Endocrinol Metab. 2014 Jul;18(4):449-54
pubmed: 25143898
Blood. 2004 May 15;103(10):3635-43
pubmed: 14630805
Biol Blood Marrow Transplant. 2020 Mar;26(3):540-545
pubmed: 31712194
Bone Marrow Transplant. 2008 Feb;41(4):393-8
pubmed: 17994116
Bone Marrow Transplant. 2012 Mar;47(3):337-41
pubmed: 22395764
Bone Marrow Transplant. 2011 Jan;46(1):1-9
pubmed: 20729922
Bone Marrow Transplant. 2019 Oct;54(10):1651-1661
pubmed: 30809037
Bone Marrow Transplant. 2016 May;51(5):738-40
pubmed: 26752146
Biol Blood Marrow Transplant. 2020 Oct;26(10):1784-1802
pubmed: 32653624
J Clin Densitom. 2019 Oct - Dec;22(4):489-500
pubmed: 31378452
Osteoporos Int. 2018 Dec;29(12):2597-2610
pubmed: 30178158
J Clin Densitom. 2016 Apr-Jun;19(2):127-40
pubmed: 27020004